New Delhi, February 24 Eris Lifesciences announced on Tuesday that it has partnered with Natco Pharma for the commercialization of semaglutide in India.
Semaglutide, a GLP-1 receptor agonist, has emerged globally as a transformative therapy for the management of Type 2 diabetes and chronic weight management, driven by robust clinical outcomes in glycemic control and weight reduction.
The collaboration leverages the complementary strengths of both companies: Eris's strong commercial and diabetes franchise presence, and Natco's manufacturing and regulatory expertise in complex formulations.
"Semaglutide represents one of the most significant therapeutic advances in metabolic care in recent years. This partnership reflects our continued commitment to strengthening our diabetes franchise with innovative and high-impact therapies," said Amit Bakshi, Chairman and MD of Eris Lifesciences, in a statement.
With Eris's strong commercial infrastructure and deep engagement in chronic therapies, the company is well-positioned to drive rapid adoption and enhance patient access in India, he added.
He further stated that Eris has been proactively preparing its commercial strategy to meaningfully participate in the GLP-1 opportunity and views this partnership as a long-term value driver for the company.
